Skip to content

Study · Non-randomized trial · n = 12 · 1994

12 results

Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.

Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F

The Journal of clinical endocrinology and metabolism1 Mar 1994Cited by 92 (Europe PMC)

PMID8126144 (opens in a new tab)DOI10.1210/jcem.78.3.8126144 (opens in a new tab)PepBankPUB-08126144
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy young volunteers, GH release after intravenous hexarelin 1 microgram/kg was about 2 times higher than after GHRH 1 microgram/kg.

    In plain wordsIn healthy young volunteers, hexarelin into a vein released about twice as much growth hormone as GHRH.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH release after intravenous hexarelin 1 microgram/kg versus GHRH
    Study

    n = 12

    Comparator
    GHRH 1 microgram/kg
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram/kg · intravenousAs given in this study (human).

    Measurements

    GH AUC
    3175 micrograms/min.L
    hexarelin 1 microgram/kg
    GH AUC
    1544 micrograms/min.L
    GHRH 1 microgram/kg

    Source sentences

    Summary
    GH release (mean +/- SEM) after the i.v. dose of 1 microgram/kg hexarelin [area under the curve (AUC), 3175 +/- 506 micrograms/min.L] was about 2 times higher than that induced by 1 microgram/kg GHRH (AUC, 1544 +/- 161 micrograms/min.L; P < 0.001).
    1 context sentence
    Summary · context
    We evaluated the GH-releasing activity of hexarelin, a new synthetic hexapeptide, after i.v. (1 and 2 micrograms/kg), sc (1.5 and 3 micrograms/kg), intranasal (20 micrograms/kg), and oral (po; 20 and 40 mg) administration to 12 healthy young volunteers.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy young volunteers, intravenous hexarelin 2 micrograms/kg elicited a further increase in GH levels compared with the 1 microgram/kg dose.

    In plain wordsIn healthy young volunteers, a higher hexarelin dose into a vein raised growth hormone further than the lower dose.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH release after intravenous hexarelin 2 micrograms/kg
    Study

    n = 12

    Comparator
    Intravenous hexarelin 1 microgram/kg
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Measurements

    GH AUC
    4422 micrograms/min.L
    2 micrograms/kg i.v.

    Source sentences

    Summary
    Hexarelin (2 micrograms/kg, i.v.) elicited a further increase in GH levels (AUC, 4422 +/- 626 micrograms/min.L) compared to the 1 microgram/kg dose.
    1 context sentence
    Summary · context
    We evaluated the GH-releasing activity of hexarelin, a new synthetic hexapeptide, after i.v. (1 and 2 micrograms/kg), sc (1.5 and 3 micrograms/kg), intranasal (20 micrograms/kg), and oral (po; 20 and 40 mg) administration to 12 healthy young volunteers.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy young volunteers, the GH response to intravenous hexarelin 2 micrograms/kg was very reproducible between two tests.

    In plain wordsIn healthy young volunteers, the growth hormone response to hexarelin into a vein was very similar when the test was repeated.

    Peptide
    Hexarelin
    Outcome
    No significant changeReproducibility of the GH response to intravenous hexarelin 2 micrograms/kg
    Study

    n = 12

    Comparator
    Repeat test
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    2 micrograms/kg · intravenousAs given in this study (human).

    Measurements

    GH AUC
    4016 micrograms/min.L
    first test
    GH AUC
    3959 micrograms/min.L
    second test

    Source sentences

    Summary
    The GH response to 2 micrograms/kg hexarelin, i.v., was very reproducible (AUC, 4016 +/- 563 vs. 3959 +/- 803 micrograms/min.L).
    1 context sentence
    Summary · context
    We evaluated the GH-releasing activity of hexarelin, a new synthetic hexapeptide, after i.v. (1 and 2 micrograms/kg), sc (1.5 and 3 micrograms/kg), intranasal (20 micrograms/kg), and oral (po; 20 and 40 mg) administration to 12 healthy young volunteers.
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy young volunteers, subcutaneous hexarelin 1.5 micrograms/kg produced a GH response, as part of a dose-dependent response.

    In plain wordsIn healthy young volunteers, hexarelin injected under the skin raised growth hormone, and a higher dose raised it more.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH release after subcutaneous hexarelin 1.5 micrograms/kg
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1.5 micrograms/kg · subcutaneousAs given in this study (human).

    Measurements

    GH AUC
    3180 micrograms.min.L
    1.5 micrograms/kg s.c.

    Source sentences

    Summary
    The sc administration of hexarelin produced a dose-dependent GH response (AUC, 3180 +/- 392 and 4459 +/- 566 micrograms.min.L with 1.5 and 3 micrograms/kg, respectively).
    1 context sentence
    Summary · context
    We evaluated the GH-releasing activity of hexarelin, a new synthetic hexapeptide, after i.v. (1 and 2 micrograms/kg), sc (1.5 and 3 micrograms/kg), intranasal (20 micrograms/kg), and oral (po; 20 and 40 mg) administration to 12 healthy young volunteers.
  5. 05HumanNon-randomized trialEfficacy outcome

    In healthy young volunteers, subcutaneous hexarelin 3 micrograms/kg produced a larger GH response than the 1.5 micrograms/kg dose.

    In plain wordsIn healthy young volunteers, the higher hexarelin dose under the skin raised growth hormone more than the lower dose.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH release after subcutaneous hexarelin 3 micrograms/kg
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    3 micrograms/kg · subcutaneousAs given in this study (human).

    Measurements

    GH AUC
    4459 micrograms.min.L
    3 micrograms/kg s.c.

    Source sentences

    Summary
    The sc administration of hexarelin produced a dose-dependent GH response (AUC, 3180 +/- 392 and 4459 +/- 566 micrograms.min.L with 1.5 and 3 micrograms/kg, respectively).
    1 context sentence
    Summary · context
    We evaluated the GH-releasing activity of hexarelin, a new synthetic hexapeptide, after i.v. (1 and 2 micrograms/kg), sc (1.5 and 3 micrograms/kg), intranasal (20 micrograms/kg), and oral (po; 20 and 40 mg) administration to 12 healthy young volunteers.
  6. 06HumanNon-randomized trialEfficacy outcome

    In healthy young volunteers, intranasal hexarelin 20 micrograms/kg induced GH release.

    In plain wordsIn healthy young volunteers, hexarelin given through the nose released growth hormone.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH release after intranasal hexarelin 20 micrograms/kg
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 micrograms/kg · intranasalAs given in this study (human).

    Measurements

    GH AUC
    2642 micrograms/min.L
    20 micrograms/kg i.n.

    Source sentences

    Summary
    Intranasal administration of 20 micrograms/kg hexarelin induced GH release (AUC, 2642 +/- 452 micrograms/min.L) similar to that caused by 1 microgram/kg, i.v.
    1 context sentence
    Summary · context
    We evaluated the GH-releasing activity of hexarelin, a new synthetic hexapeptide, after i.v. (1 and 2 micrograms/kg), sc (1.5 and 3 micrograms/kg), intranasal (20 micrograms/kg), and oral (po; 20 and 40 mg) administration to 12 healthy young volunteers.
  7. 07HumanNon-randomized trialEfficacy outcome

    In healthy young volunteers, GH release after intranasal hexarelin was similar to that after intravenous hexarelin 1 microgram/kg.

    In plain wordsIn healthy young volunteers, hexarelin through the nose released about as much growth hormone as a low dose into a vein.

    Peptide
    Hexarelin
    Outcome
    No significant changeGH release after intranasal versus intravenous hexarelin
    Study

    n = 12

    Comparator
    Intravenous hexarelin 1 microgram/kg
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 micrograms/kg · intranasalAs given in this study (human).

    Source sentences

    Summary
    Intranasal administration of 20 micrograms/kg hexarelin induced GH release (AUC, 2642 +/- 452 micrograms/min.L) similar to that caused by 1 microgram/kg, i.v.
    1 context sentence
    Summary · context
    We evaluated the GH-releasing activity of hexarelin, a new synthetic hexapeptide, after i.v. (1 and 2 micrograms/kg), sc (1.5 and 3 micrograms/kg), intranasal (20 micrograms/kg), and oral (po; 20 and 40 mg) administration to 12 healthy young volunteers.
  8. 08HumanNon-randomized trialEfficacy outcome

    In healthy young volunteers, oral hexarelin 20 mg increased GH levels, as part of a dose-related response.

    In plain wordsIn healthy young volunteers, hexarelin taken by mouth raised growth hormone, and a higher dose raised it more.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH release after oral hexarelin 20 mg
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 mg · oralAs given in this study (human).

    Measurements

    GH AUC
    2278 micrograms/min.L
    20 mg p.o.

    Source sentences

    Summary
    Twenty and 40 mg hexarelin, po, produced a dose-related increase in GH levels (AUC, 2278 +/- 442 and 4079 +/- 514 micrograms/min.L).
    1 context sentence
    Summary · context
    We evaluated the GH-releasing activity of hexarelin, a new synthetic hexapeptide, after i.v. (1 and 2 micrograms/kg), sc (1.5 and 3 micrograms/kg), intranasal (20 micrograms/kg), and oral (po; 20 and 40 mg) administration to 12 healthy young volunteers.
  9. 09HumanNon-randomized trialEfficacy outcome

    In healthy young volunteers, oral hexarelin 40 mg increased GH levels more than the 20 mg dose.

    In plain wordsIn healthy young volunteers, the higher oral hexarelin dose raised growth hormone more than the lower dose.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH release after oral hexarelin 40 mg
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    40 mg · oralAs given in this study (human).

    Measurements

    GH AUC
    4079 micrograms/min.L
    40 mg p.o.

    Source sentences

    Summary
    Twenty and 40 mg hexarelin, po, produced a dose-related increase in GH levels (AUC, 2278 +/- 442 and 4079 +/- 514 micrograms/min.L).
    1 context sentence
    Summary · context
    We evaluated the GH-releasing activity of hexarelin, a new synthetic hexapeptide, after i.v. (1 and 2 micrograms/kg), sc (1.5 and 3 micrograms/kg), intranasal (20 micrograms/kg), and oral (po; 20 and 40 mg) administration to 12 healthy young volunteers.
  10. 10HumanNon-randomized trialPharmacokinetics

    In healthy young volunteers, the biological bioavailability of subcutaneous hexarelin was 77.0%.

    In plain wordsIn healthy young volunteers, hexarelin injected under the skin had a biological bioavailability of 77.0%.

    Peptide
    Hexarelin
    Outcome
    Not applicableBiological bioavailability by subcutaneous route
    Study

    n = 12

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.5 and 3 micrograms/kg · subcutaneousAs given in this study (human).

    Measurements

    Biological bioavailability
    77%
    subcutaneous

    Source sentences

    Summary
    Biological bioavailabilities were 77.0 +/- 10.5%, 4.8 +/- 0.9%, and 0.3 +/- 0.1% for the sc, intranasal, and po routes, respectively.
    1 context sentence
    Summary · context
    We evaluated the GH-releasing activity of hexarelin, a new synthetic hexapeptide, after i.v. (1 and 2 micrograms/kg), sc (1.5 and 3 micrograms/kg), intranasal (20 micrograms/kg), and oral (po; 20 and 40 mg) administration to 12 healthy young volunteers.
  11. 11HumanNon-randomized trialPharmacokinetics

    In healthy young volunteers, the biological bioavailability of intranasal hexarelin was 4.8%.

    In plain wordsIn healthy young volunteers, hexarelin through the nose had a biological bioavailability of 4.8%.

    Peptide
    Hexarelin
    Outcome
    Not applicableBiological bioavailability by intranasal route
    Study

    n = 12

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    20 micrograms/kg · intranasalAs given in this study (human).

    Measurements

    Biological bioavailability
    4.8%
    intranasal

    Source sentences

    Summary
    Biological bioavailabilities were 77.0 +/- 10.5%, 4.8 +/- 0.9%, and 0.3 +/- 0.1% for the sc, intranasal, and po routes, respectively.
    1 context sentence
    Summary · context
    We evaluated the GH-releasing activity of hexarelin, a new synthetic hexapeptide, after i.v. (1 and 2 micrograms/kg), sc (1.5 and 3 micrograms/kg), intranasal (20 micrograms/kg), and oral (po; 20 and 40 mg) administration to 12 healthy young volunteers.
  12. 12HumanNon-randomized trialPharmacokinetics

    In healthy young volunteers, the biological bioavailability of oral hexarelin was 0.3%.

    In plain wordsIn healthy young volunteers, hexarelin taken by mouth had a biological bioavailability of 0.3%.

    Peptide
    Hexarelin
    Outcome
    Not applicableBiological bioavailability by oral route
    Study

    n = 12

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    20 and 40 mg · oralAs given in this study (human).

    Measurements

    Biological bioavailability
    0.3%
    oral

    Source sentences

    Summary
    Biological bioavailabilities were 77.0 +/- 10.5%, 4.8 +/- 0.9%, and 0.3 +/- 0.1% for the sc, intranasal, and po routes, respectively.
    1 context sentence
    Summary · context
    We evaluated the GH-releasing activity of hexarelin, a new synthetic hexapeptide, after i.v. (1 and 2 micrograms/kg), sc (1.5 and 3 micrograms/kg), intranasal (20 micrograms/kg), and oral (po; 20 and 40 mg) administration to 12 healthy young volunteers.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.